MCID: SYS003
MIFTS: 45

Systolic Heart Failure

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Systolic Heart Failure

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 11 5 14 16
Heart Failure, Systolic 43 71

Classifications:



External Ids:

Disease Ontology 11 DOID:9651
ICD9CM 34 428.2
MeSH 43 D054143
SNOMED-CT 68 417996009
UMLS 71 C1135191

Summaries for Systolic Heart Failure

MalaCards based summary: Systolic Heart Failure, also known as heart failure, systolic, is related to peripartum cardiomyopathy and central sleep apnea. An important gene associated with Systolic Heart Failure is MIR423 (MicroRNA 423), and among its related pathways/superpathways are Cardiac conduction and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Verapamil and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are muscle and homeostasis/metabolism

Related Diseases for Systolic Heart Failure

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
# Related Disease Score Top Affiliating Genes
1 peripartum cardiomyopathy 31.8 TTN NR3C2 NPPB MYH6 MIR423 ACE
2 central sleep apnea 31.0 REN NPPB CRP ACE
3 sleep apnea 30.7 REN NPPB IL6 EDN1 CRP ACE
4 atrial fibrillation 30.6 TNNI3 NR3C2 NPPB IL6 CRP AGTR1
5 left bundle branch hemiblock 30.5 TTN TNNT2 TNNI3 REN NR3C2 NPPB
6 deficiency anemia 30.5 SERPINA3 REN MME IL6 CRP ACE
7 rheumatic heart disease 30.5 NPPB IL6 ACE
8 cardiomyopathy, familial hypertrophic, 1 30.5 TTN TNNT2 TNNI3 MYH6
9 nutritional deficiency disease 30.5 SERPINA3 IL6 CRP
10 hypothyroidism 30.4 REN NPPB LGALS3 CRP ACE
11 chagas disease 30.4 NPPB LGALS3 IL6 ADRB1 ACE
12 uremia 30.4 REN IL6 CRP ACE
13 pulmonary disease, chronic obstructive 30.4 SERPINA3 PDE5A NPPB IL6 CRP ACE
14 pure autonomic failure 30.3 REN PDE5A ACE
15 mitral valve insufficiency 30.3 TTN TNNT2 TNNI3 REN NR3C2 NPPB
16 wild-type amyloidosis 30.3 SERPINA3 NPPB
17 apnea, obstructive sleep 30.3 REN NR3C2 NPPB IL6 EDN1 CRP
18 acute kidney failure 30.3 REN IL6 ACE
19 cardiac arrest 30.2 TNNT2 TNNI3 NPPB CRP ACE
20 kidney disease 30.2 REN NR3C2 NPPB IL6 EDN1 CRP
21 angina pectoris 30.2 TNNI3 NPPB IL6 EDN1 CRP ACE
22 autonomic nervous system disease 30.2 REN IL6 CRP ACE
23 amyloidosis 30.1 SERPINA3 NPPB MME IL6 CRP
24 gastroenteritis 30.1 REN IL6 CRP
25 pulmonary hypertension 30.1 REN PDE5A NPPB IL6 EDN1 CRP
26 polycythemia 30.1 REN EDN1 CRP ACE
27 sleep disorder 30.1 REN IL6 EDN1 CRP ACE
28 atrioventricular block 30.1 TNNT2 TNNI3 NPPB MYH6 CRP ACE
29 vascular disease 30.1 PDE5A IL6 EDN1 CRP AGTR1 ACE
30 intermittent claudication 30.1 TNNT2 IL6 CRP ACE
31 coronary stenosis 30.0 TNNI3 NPPB IL6 CRP ACE
32 peripheral vascular disease 30.0 SERPINA3 REN PDE5A IL6 EDN1 CRP
33 peripheral artery disease 29.9 REN NPPB MIR423 IL6 CRP ACE
34 arteries, anomalies of 29.9 TNNI3 SERPINA3 REN MIR423 IL6 EDN1
35 acute myocarditis 29.9 TNNT2 TNNI3 REN NPPB IL6 CRP
36 pericardial effusion 29.9 TNNT2 TNNI3 REN NPPB IL6 CRP
37 chronic kidney disease 29.8 TNNT2 TNNI3 REN NR3C2 NPPB IL6
38 transient cerebral ischemia 29.8 SERPINA3 REN NPPB IL6 CRP ACE
39 lung disease 29.8 SERPINA3 NPPB IL6 EDN1 ACE
40 liver cirrhosis 29.8 SERPINA3 REN IL6 EDN1
41 atherosclerosis susceptibility 29.8 IL6 EDN1 CRP AGTR1 ACE
42 pulmonary valve insufficiency 29.8 REN PDE5A NPPB EDN1 CRP ACE
43 myopathy 29.7 TTN TNNT2 TNNI3 SERPINA3 MYH6 MIR423
44 tricuspid valve insufficiency 29.7 TNNT2 TNNI3 REN PDE5A NR3C2 NPPB
45 lipid metabolism disorder 29.7 SERPINA3 REN PDE5A IL6 EDN1 CRP
46 pulmonary edema 29.7 TNNT2 TNNI3 REN NPPB EDN1 CRP
47 myocarditis 29.6 TTN TNNT2 TNNI3 NPPB MYH6 IL6
48 conn's syndrome 29.6 REN NR3C2 IL6 EDN1 CRP AGTR1
49 aortic valve disease 1 29.5 REN NPPB MYH6 MIR423 EDN1 CRP
50 connective tissue disease 29.5 SERPINA3 MIR92B MIR423 IL6 EDN1 CRP

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure

Symptoms & Phenotypes for Systolic Heart Failure

MGI Mouse Phenotypes related to Systolic Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.85 ADRB1 EDN1 IL6 MYH6 NPPB NR3C2
2 homeostasis/metabolism MP:0005376 9.8 ACE ADRB1 AGTR1 CRP EDN1 IL6
3 cardiovascular system MP:0005385 9.47 ACE ADRB1 AGTR1 CRP EDN1 IL6

Drugs & Therapeutics for Systolic Heart Failure

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
7
Bisoprolol Approved Phase 4 66722-44-9 2405
8
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
9
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
10
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
11
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
12
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
13
Hydralazine Approved Phase 4 86-54-4 3637
14
Iron Approved Phase 4 7439-89-6 29936
15
Eplerenone Approved Phase 4 107724-20-9 443872
16
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
17
Simendan Investigational Phase 4 131741-08-7
18 calcium channel blockers Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Sacubitril and valsartan sodium hydrate drug combination Phase 4
21
Angiotensinogen Phase 4 16133225
22 HIV Protease Inhibitors Phase 4
23 Giapreza Phase 4
24
protease inhibitors Phase 4
25 Adrenergic beta-1 Receptor Antagonists Phase 4
26 Adrenergic Antagonists Phase 4
27 Neurotransmitter Agents Phase 4
28 Sympatholytics Phase 4
29
Sitagliptin Phosphate Phase 4 654671-77-9
30 Dipeptidyl-Peptidase IV Inhibitors Phase 4
31 Incretins Phase 4
32 Purinergic P2Y Receptor Antagonists Phase 4
33
Prasugrel Hydrochloride Phase 4 389574-19-0
34 Platelet Aggregation Inhibitors Phase 4
35 Angiotensin II Type 1 Receptor Blockers Phase 4
36 Angiotensin-Converting Enzyme Inhibitors Phase 4
37 Chrysarobin Phase 4
38 Adrenergic beta-Antagonists Phase 4
39 Adrenergic Agents Phase 4
40 Antihypertensive Agents Phase 4
41 Mineralocorticoids Phase 4
42 Mineralocorticoid Receptor Antagonists Phase 4
43 Hormones Phase 4
44 Hormone Antagonists Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 diuretics Phase 4
47 Vasodilator Agents Phase 4
48 Cardiotonic Agents Phase 4
49 Phosphodiesterase Inhibitors Phase 4
50 Phosphodiesterase 3 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 187)
# Name Status NCT ID Phase Drugs
1 Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations Unknown status NCT03764722 Phase 4 Levosimendan
2 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
3 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
4 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
5 The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). Unknown status NCT03871699 Phase 4 Ferric carboxymaltose
6 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
7 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
8 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
9 Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® Unknown status NCT04570865 Phase 4 Dapagliflozin
10 Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton Unknown status NCT03553303 Phase 4 Sacubitril / Valsartan Oral Tablet
11 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Unknown status NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
12 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
13 A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure Completed NCT02920918 Phase 4 Canagliflozin;Sitagliptin
14 Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
15 SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients. Completed NCT01434615 Phase 4
16 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
17 Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial Completed NCT02401126 Phase 4
18 Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction Completed NCT05387967 Phase 4 Sacubitril/valsartan
19 Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF). Completed NCT02970669 Phase 4 sacubitril/valsartan (LCZ696);enalapril;matching placebo sacubitril/valsartan (LCZ696);matching placebo enalapril
20 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
21 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2 Recruiting NCT03036462 Phase 4 Iron;Saline
22 Pulse Reduction On Beta-blocker and Ivabradine Therapy Active, not recruiting NCT02973594 Phase 4 Ivabradine;Placebo
23 Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? Enrolling by invitation NCT03984591 Phase 4 Eplerenone;Spironolactone
24 Levosimendan In Ambulatory Heart Failure Patients Not yet recruiting NCT04705337 Phase 4 Levosimendan
25 Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure Unknown status NCT01913847 Phase 3 Sildenafil;Placebo
26 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
27 MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
28 Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure Unknown status NCT01639378 Phase 3
29 The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
30 Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure Completed NCT00206310 Phase 3 CRESTOR
31 The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure Completed NCT00232180 Phase 3 Eplerenone
32 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Completed NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
33 Spinal Cord Stimulation For Heart Failure As A Restorative Treatment Completed NCT01362725 Phase 2, Phase 3
34 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction Completed NCT03917459 Phase 3 LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo
35 Blended Collaborative Care for Heart Failure and Co-Morbid Depression Completed NCT02044211 Phase 2, Phase 3
36 Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP Completed NCT04420481 Phase 3 Somatropin;Placebo
37 Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study Recruiting NCT02051712 Phase 3
38 A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy. Recruiting NCT03388593 Phase 3 rhNRG-1;Placebo
39 Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency Recruiting NCT03991000 Phase 3 Ferric carboxymaltose;Saline
40 Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life Recruiting NCT04201015 Phase 2, Phase 3
41 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy Active, not recruiting NCT04468529 Phase 3 Recombinant human Neuregulin for injection;Placebo
42 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01131637 Phase 3 rhNRG-1;placebo
43 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure Terminated NCT01646515 Phase 3 Placebo;Udenafil (Zydena)
44 A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure Terminated NCT01214096 Phase 3 rhNRG-1;placebo
45 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01439789 Phase 3 rhNRG-1;Placebo
46 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01541202 Phase 3 rhNRG-1;Placebo
47 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01439893 Phase 3 rhNRG-1;Placebo
48 MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA) Terminated NCT01872234 Phase 3
49 GutHeart: Targeting Gut Microbiota to Treat Heart Failure Unknown status NCT02637167 Phase 2 Rifaximin;Saccharomyces boulardii
50 A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study. Completed NCT02040233 Phase 2 BAY1067197 (10 mg);BAY1067197;Placebo (10 mg);Placebo

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Genetic Tests for Systolic Heart Failure

Anatomical Context for Systolic Heart Failure

Organs/tissues related to Systolic Heart Failure:

MalaCards : Heart, Brain, Kidney, Spinal Cord, Endothelial, Breast, Skeletal Muscle

Publications for Systolic Heart Failure

Articles related to Systolic Heart Failure:

(show top 50) (show all 2539)
# Title Authors PMID Year
1
Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE-HF major sub study. 62
35840352 2022
2
Insights into the Mechanism of the Cardiac Drug Omecamtiv Mecarbil─A Computational Study. 62
36448224 2022
3
dATP elevation induces myocardial metabolic remodeling to support improved cardiac function. 62
36470336 2022
4
Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study. 62
36056955 2022
5
Sepsis, Septic Shock, and Differences in Cardiovascular Event Occurrence. 62
35236176 2022
6
Early predicting improvement of severe systolic heart failure by left atrial volume. 62
36409354 2022
7
Myocardial fibrosis and ventricular ectopy in patients with non-ischemic systolic heart failure: results from the DANISH trial. 62
36434345 2022
8
Pulmonary artery-to-aorta ratio on high-resolution computed tomography and exercise performance in systolic heart failure. 62
35588892 2022
9
Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure. 62
34727343 2022
10
Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry. 62
36295637 2022
11
Effect of adaptive servo-ventilation for central sleep apnoea in systolic heart failure on muscle sympathetic nerve activity: a SERVE-HF randomised ancillary study. 62
36229051 2022
12
Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction. 62
35894764 2022
13
Using the C2HEST Score for Predicting Postoperative Atrial Fibrillation After Cardiac Surgery: A Report From the Western Denmark Heart Registry, the Danish National Patient Registry, and the Danish National Prescription Registry. 62
35581051 2022
14
Dilated Cardiomyopathy and Systolic Heart Failure in a Female Patient With Danon Disease. 62
36447708 2022
15
The serum concentration of brain‑derived neurotrophic factor is lower in ambulatory and clinically stable patients with more advanced systolic heart failure. 62
35916461 2022
16
Cardiac resynchronization therapy response in cardiac sarcoidosis. 62
35870183 2022
17
Unsupervised machine learning demonstrates the prognostic value of TAPSE/PASP ratio among hospitalized patients with COVID-19. 62
35907784 2022
18
Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure. 62
36142977 2022
19
Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. 62
35942877 2022
20
Association between DLCO index and the severity of heart failure: a cross-sectional study. 62
36082926 2022
21
Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair. 62
34983911 2022
22
Dapagliflozin for patients with heart failure and reduced ejection fraction. 62
36007119 2022
23
Effects of adaptive left bundle branch-optimized cardiac resynchronization therapy: a single centre experience. 62
35933334 2022
24
For the love of muscles: a bodybuilder with complicated left ventricular heart failure. 62
35972452 2022
25
Society for Maternal-Fetal Medicine Consult Series #61: Anticoagulation in pregnant patients with cardiac disease. 62
35337804 2022
26
A strange way of breathing in a patient with advanced systolic heart failure. 62
35953097 2022
27
Poor efficacy of oral iron replacement therapy in pediatric patients with heart failure. 62
34629125 2022
28
Identification of Potential Biomarkers Associated with Dilated Cardiomyopathy by Weighted Gene Coexpression Network Analysis. 62
36042172 2022
29
Impact of signal-averaged electrocardiography findings on appropriate shocks in prophylactic implantable cardioverter defibrillator patients with nonischemic systolic heart failure. 62
35974317 2022
30
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. 62
35926931 2022
31
Effects of Renin-Angiotensin-Aldosterone System Inhibition on Left Ventricular Hypertrophy, Diastolic Function, and Functional Status in Patients With Hypertrophic Cardiomyopathy: A Systematic Review. 62
35949750 2022
32
Left bundle branch pacing in a ventricular pacing dependent patient with heart failure: A case report. 62
36051124 2022
33
First-in-man Implantation of a Cardiac Microcurrent Device for Chronic Systolic Heart Failure. 62
34324448 2022
34
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. 62
35758031 2022
35
ln silico simulation of the interaction among autoregulatory mechanisms regulating cerebral blood flow rate in the healthy and systolic heart failure conditions during exercise. 62
35508787 2022
36
Efficacy of Doppler echocardiography-guided ivabradine therapy. 62
35789418 2022
37
Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. 62
35473780 2022
38
[Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.] 62
35989624 2022
39
Hemodynamic and Clinical Determinants of Left Atrial Enlargement in Liver Transplant Candidates. 62
35341576 2022
40
In nonischemic systolic HF, prophylactic ICDs did not reduce all-cause mortality vs. usual care at 10 y. 62
35667075 2022
41
Pathophysiologic mechanisms of lupus-induced myocardial injury elucidated by cardiovascular magnetic resonance imaging. 62
35303625 2022
42
An Unusual Case of Dilated Cardiomyopathy in Wegner's Granulomatosis. 62
35832755 2022
43
In-Hospital Outcomes in Pregnancy After Heart Transplantation. 62
35331474 2022
44
Predictive Value of C2HEST Score for Atrial Fibrillation Recurrence Following Successful Cryoballoon Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation. 62
35583221 2022
45
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. 62
35394821 2022
46
Selvester QRS score predicts improvement of LVEF in atrial fibrillation patients with systolic heart failure. 62
35383970 2022
47
Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice. 62
34459280 2022
48
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure. 62
35378982 2022
49
Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial. 62
35410445 2022
50
Echocardiographic Parameters and Outcomes in Methamphetamine-Associated Heart Failure: A Propensity Score-Weighted Analysis. 62
35465084 2022

Variations for Systolic Heart Failure

ClinVar genetic disease variations for Systolic Heart Failure:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TTN NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys) SNV Likely Benign
47210 rs146496197 GRCh37: 2:179640923-179640923
GRCh38: 2:178776196-178776196
2 DSP NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn) SNV Benign
44963 rs34884895 GRCh37: 6:7585795-7585795
GRCh38: 6:7585562-7585562
3 DTNA NM_001386795.1(DTNA):c.1438C>A (p.Pro480Thr) SNV Benign
46411 rs77320474 GRCh37: 18:32431798-32431798
GRCh38: 18:34851834-34851834
4 DSG2 NM_001943.5(DSG2):c.1543G>A (p.Val515Ile) SNV Benign
36010 rs2230235 GRCh37: 18:29116284-29116284
GRCh38: 18:31536321-31536321
5 ANKRD1 NM_014391.3(ANKRD1):c.827C>T (p.Ala276Val) SNV Benign
45639 rs35550482 GRCh37: 10:92675322-92675322
GRCh38: 10:90915565-90915565

Expression for Systolic Heart Failure

Search GEO for disease gene expression data for Systolic Heart Failure.

Pathways for Systolic Heart Failure

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 TTN TNNT2 TNNI3 PDE5A MYH6 MME
2 11.56 TNNT2 TNNI3 IL6
3 11.42 MYH6 IL6 EDN1
4 11.22 TNNT2 TNNI3 MYH6
5
Show member pathways
11.13 TTN TNNT2 TNNI3 MYH6
6
Show member pathways
11.08 REN NR3C2 MME AGTR1 ACE
7
Show member pathways
11.02 IL6 AGTR1 ACE

GO Terms for Systolic Heart Failure

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.6 SERPINA3 REN NPPB MIR92B MIR423 MIR1306
2 cardiac myofibril GO:0097512 9.56 TNNT2 TNNI3
3 myofibril GO:0030016 9.46 TNNT2 TNNI3 MYH6
4 cardiac Troponin complex GO:1990584 9.26 TNNT2 TNNI3

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 10.15 REN MME AGTR1 ACE
2 muscle contraction GO:0006936 10.03 MYH6 TNNI3 TNNT2 TTN
3 sarcomere organization GO:0045214 10.01 TTN TNNT2 MYH6
4 acute-phase response GO:0006953 10 CRP IL6 SERPINA3
5 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.93 TNNT2 TNNI3 MYH6
6 bradykinin catabolic process GO:0010815 9.88 MME ACE
7 regulation of vasoconstriction GO:0019229 9.88 EDN1 AGTR1 ACE
8 body fluid secretion GO:0007589 9.87 NPPB EDN1
9 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.86 AGTR1 ACE
10 vasoconstriction GO:0042310 9.85 EDN1 CRP ACE
11 hormone catabolic process GO:0042447 9.81 MME ACE
12 substance P catabolic process GO:0010814 9.8 MME ACE
13 renin-angiotensin regulation of aldosterone production GO:0002018 9.78 REN AGTR1
14 cardiac muscle contraction GO:0060048 9.76 TTN TNNT2 TNNI3 MYH6
15 amyloid-beta metabolic process GO:0050435 9.73 ACE MME REN
16 striated muscle contraction GO:0006941 9.72 TTN TNNI3 MYH6
17 blood vessel diameter maintenance GO:0097746 9.5 NPPB EDN1 AGTR1 ACE
18 regulation of blood pressure GO:0008217 9.28 REN NPPB MYH6 EDN1 ACE

Molecular functions related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 exopeptidase activity GO:0008238 9.46 MME ACE
2 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
3 bradykinin receptor binding GO:0031711 8.92 AGTR1 ACE

Sources for Systolic Heart Failure

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....